The Oncology InstituteTOIIW 56 14-Day RSI is 100.00 as of Jul. 02, 2026. GuruFocus rates TOIIW with a GF Score™ of 56/100. The stock has 6 warning signs investors should review. Among 701 Healthcare Providers & Services companies, The Oncology Institute ranks worse than 82.74% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for The Oncology Institute's 14-Day RSI or its related term are showing as below:
TOIIW's 14-Day RSI is ranked worse than 82.74% of 701
companies
in the Healthcare Providers & Services industry
Industry Median: 48.53
vs TOIIW: 100.00
The Oncology Institute (NAS:TOIIW) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
The Oncology Institute 14-Day RSI Related Terms
TOIIW vs CYH, SRTA, CCRN: 14-Day RSI Comparison
For the Medical Care Facilities subindustry, The Oncology Institute's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Oncology Institute 14-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where The Oncology Institute's 14-Day RSI falls into.
The Oncology Institute (NAS:TOIIW) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute (TOIIW) has a 14-Day RSI of 100.00 as of Jul. 02, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on The Oncology Institute and its competitors. According to the industry distribution chart, The Oncology Institute ranks #580 out of 701 companies in the Healthcare Providers & Services industry, placing it in the top 82.7%.
Is The Oncology Institute's 14-Day RSI too high?
The Oncology Institute's current 14-Day RSI is 100.00. The Healthcare Providers & Services industry median 14-Day RSI is 48.53. The Oncology Institute's value of 100.00 is 106.1% above this industry median. Based on the distribution chart, The Oncology Institute ranks #580 out of 701 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, The Oncology Institute has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's 14-Day RSI compare to CYH and SRTA?
According to the Healthcare Providers & Services industry distribution chart, The Oncology Institute ranks #580 out of 701 companies for 14-Day RSI. This places The Oncology Institute in the lower half of its industry. The industry median 14-Day RSI is 48.53. The Oncology Institute's value of 100.00 is 106.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Healthcare Providers & Services company?
The median 14-Day RSI among Healthcare Providers & Services companies is 48.53, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Oncology Institute's current 14-Day RSI of 100.00 is 106.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on The Oncology Institute and its competitors. For the Healthcare Providers & Services industry, the median 14-Day RSI is 48.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Oncology Institute's current 14-Day RSI is 100.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
The Oncology Institute (TOIIW) has a current 14-Day RSI of 100.00. The current 14-Day RSI is 100.00 and 106.1% above the Healthcare Providers & Services industry median of 48.53. The Oncology Institute's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For The Oncology Institute (TOIIW), the current 14-Day RSI is 100.00 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score
Get the complete analysis for TOIIW
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOIIW has been successfully added to your 